ACOR Acorda Therapeutics Inc.

-0.45  -2%
Previous Close 29.9
Open 29.95
Price To Book 2.52
Market Cap 1386107718
Shares 47,066,476
Volume 753,001
Short Ratio 12.99
Av. Daily Volume 575,350

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
Improve walking in patients with multiple sclerosis
Phase 1 complete. Noted November 2017 that it will not advance into a Phase 2 study by the end of 2017, as previously expected. Evaluating next steps.
Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued.
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Post stroke deficits
Phase 3 data released February 9, 2017 - primary endpoint met. NDA filing announced June 29, 2017. However, FDA issued a Refuse-To-File letter August 30, 2017. New PDUFA date October 5, 2018.
OFF episodes of Parkinson’s disease (PD)
Phase 2 data due 2Q 2018.
Primary Sclerosing Cholangitis

Latest News

  1. Acorda to Present Data for INBRIJA™ (levodopa inhalation powder) at 2nd Pan American Parkinson’s Disease and Movement Disorders Congress
  2. Acorda Therapeutics (ACOR) in Focus: Stock Moves 8.9% Higher
  3. Today’s Research Reports on Stocks to Watch: Acorda Therapeutics and TrovaGene
  4. Here's Why Acorda Therapeutics Rose as Much as 30.3% Today
  5. Acorda (ACOR) Up 13.4% Since Earnings Report: Can It Continue?
  6. Stock Performance Review on ACADIA Pharma and Three Other Biotech Stocks
  7. Blog Exposure - Gilead Announces Approval of Epclusa in China
  8. Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA
  9. Acorda Announces EMA Validation of the MAA Submission for INBRIJA™ (levodopa inhalation powder)
  10. Detailed Research: Economic Perspectives on First American, Greenhill & Co., Acorda Therapeutics, Deckers Outdoor, World Fuel Services, and Spirit Aerosystems — What Drives Growth in Today's Competitive Landscape
  11. See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
  12. Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y
  13. Edited Transcript of ACOR earnings conference call or presentation 2-May-18 12:30pm GMT
  14. Acorda: 1Q Earnings Snapshot
  15. Acorda Provides Financial and Pipeline Update for First Quarter 2018
  16. Analysts’ Ratings for Amicus and Its Peers in April
  17. New Strong Sell Stocks for April 18th
  18. Acorda to Present New Data For INBRIJA™ (levodopa inhalation powder) at 70th American Academy of Neurology Annual Meeting
  19. How Analysts Rate Regenxbio and Peers in April 2018